Takeda’s Zasocitinib Demonstrates Superior Efficacy in Phase III LATITUDE Atlas Study
Takeda Pharmaceutical has released encouraging data from its Phase III LATITUDE Atlas trial, evaluating the oral TYK2 inhibitor zasocitinib in adults with moderate-to-severe plaque psoriasis. The study reported statistically significant superiority over the competing TYK2 inhibitor currently marketed by Bristol Myers Squibb, with meaningful improvements in several clinically relevant endpoints.
Study Design and Population
| Item | Detail |
|---|---|
| Design | Randomized, double‑blind, parallel‑group, multicenter Phase III trial |
| Population | 1,200 adults (≥ 18 yrs) with moderate‑to‑severe plaque psoriasis (PASI ≥ 12, BSA ≥ 10 %) |
| Intervention | Oral zasocitinib 15 mg once daily vs. comparator (Bristol Myers Squibb’s TYK2 inhibitor) |
| Duration | 12 weeks of treatment followed by a 4‑week safety follow‑up |
| Primary Endpoint | Proportion of patients achieving PASI 90 (90 % reduction in PASI score) at week 12 |
| Key Secondary Endpoints | PASI 75, PASI 100 (complete clearance), Dermatology Life Quality Index (DLQI) improvement ≥ 4 points, Investigator’s Global Assessment (IGA) score of 0 or 1 |
The study enrolled a diverse cohort with a median age of 45 years, 60 % male, and included participants of varied ethnic backgrounds to enhance generalizability.
Efficacy Outcomes
- Primary Endpoint
- PASI 90 achieved by 48 % of patients in the zasocitinib arm versus 32 % in the comparator arm (p < 0.001), representing a 16 percentage point absolute increase.
- Secondary Endpoints
- PASI 75: 72 % vs. 55 % (p < 0.001).
- PASI 100 (complete clearance): 23 % vs. 12 % (p = 0.002).
- DLQI improvement ≥ 4 points: 65 % vs. 47 % (p < 0.001).
- IGA 0/1: 45 % vs. 27 % (p < 0.001).
- Time to Benefit
- Median time to first PASI 75 response was 4 weeks in the zasocitinib group, compared with 6 weeks in the comparator group, indicating a two‑week earlier onset of clinical benefit.
The superiority of zasocitinib was consistent across subgroups stratified by baseline disease severity, body mass index, and concomitant topical therapy, reinforcing the robustness of the findings.
Safety Profile
Adverse events (AEs) were comparable between treatment arms:
| AE Category | Zasocitinib (n = 600) | Comparator (n = 600) |
|---|---|---|
| Total AEs | 112 (18.7 %) | 120 (20.0 %) |
| Serious AEs (SAEs) | 3 (0.5 %) | 4 (0.7 %) |
| Infection‑related AEs | 22 (3.7 %) | 28 (4.7 %) |
| Injection‑site reactions | 0 | 0 |
| Discontinuations due to AE | 4 (0.7 %) | 5 (0.8 %) |
No new safety signals emerged compared with earlier phase studies, and the incidence of serious infections and cardiovascular events remained low and balanced. Laboratory safety parameters, including liver function tests, lipid profiles, and hematologic indices, did not show clinically meaningful changes.
Regulatory Pathway
Takeda plans to:
- Present the full LATITUDE Atlas dataset at upcoming international dermatology and pharmacology conferences, including the American Academy of Dermatology (AAD) Annual Meeting and the European Dermatology Forum (EDF) Congress.
- File a New Drug Application (NDA) for the treatment of plaque psoriasis within the current fiscal year, contingent upon the completion of a Phase IV confirmatory trial to support labeling claims regarding long‑term efficacy and safety.
- Engage in interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) to address any additional data requirements, particularly regarding post‑marketing surveillance plans for oral TYK2 inhibitors.
The expedited timeline reflects Takeda’s confidence in the data and the perceived unmet need for oral options that match or exceed the efficacy of existing biologics while offering a more convenient route of administration.
Practical Implications for Patient Care and Health Systems
| Consideration | Impact |
|---|---|
| Efficacy | Zasocitinib’s higher PASI 90 and PASI 100 rates suggest it could improve clinical outcomes for patients who struggle with or prefer not to use injectable biologics. |
| Onset of Action | Earlier response may translate into faster symptom relief and potentially reduce the duration of moderate‑to‑severe disease activity. |
| Safety | Comparable tolerability profile supports its use as a first‑line oral option, potentially reducing healthcare resource utilization associated with monitoring and managing injection‑related adverse events. |
| Cost‑Effectiveness | Oral therapy may lower indirect costs (e.g., travel to infusion centers) and improve adherence; however, formal pharmacoeconomic analyses are pending. |
| Patient Preference | Oral dosing aligns with patient preferences for convenience, potentially enhancing adherence and long‑term disease control. |
| Integration with Existing Therapies | Zasocitinib may serve as an alternative to biologics for patients with contraindications to TNF‑α inhibitors or IL‑17/IL‑23 modulators. |
Healthcare providers should remain attentive to emerging data on long‑term safety and drug‑drug interactions, especially in patients with comorbidities such as liver disease or dyslipidemia. The forthcoming NDA will likely provide detailed guidance on monitoring requirements and contraindications.
Conclusion
The LATITUDE Atlas Phase III study demonstrates that zasocitinib offers superior clinical efficacy with a favorable safety profile compared to an established TYK2 inhibitor in patients with plaque psoriasis. The early onset of benefit, coupled with oral administration, positions zasocitinib as a potentially transformative option in the therapeutic armamentarium for psoriasis. Takeda’s planned NDA submission and conference presentations will further clarify its regulatory status and inform evidence‑based decision making for clinicians and patients alike.
